In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Weight loss drugs like Ozempic and Wegovy cost an average of $1,083 per month if you pay full price ... For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing ... and half maintained it after three years. Adults lost an average of 8% of their body weight over 56 weeks ...

Similar findings also are possible for the new wave of anti-obesity drugs like Wegovy and Zepbound, given that they provide ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...